The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move strengthening its position in the home healthcare market, the U.S. Food and Drug Administration (FDA) has expanded the clearance of DexCom's Stelo Glucose Biosensor System for over-the-counter use in children aged two and older, marking a historic first for pediatric glucose monitoring. This regulatory milestone coincides with Deutsche Bank initiating coverage on DexCom and Insulet with Buy ratings, setting price targets of $86 and $190 respectively, citing significant undervaluation in the current market.
Sign in to access this content
Sign InThis regulatory expansion underscores DexCom's ability to penetrate new demographics, following a strong Q1 2024 performance where the company reported $1.0 billion in revenue, a 24% year-over-year increase according to company filings. While market data shows Abbott Laboratories remains a formidable peer in the continuous glucose monitoring space, DexCom's new over-the-counter (OTC) pediatric advantage provides a strategic edge in direct-to-consumer access, supporting the analyst view that prior selling pressure has likely bottomed out.
Regarding price action, DXCM is currently trading at $69.07 (close June 22, 2026), implying that Deutsche Bank's $86 target offers a potential upside of 24.5%. Investors should keep a close watch on upcoming US economic catalysts, including inflation data and retail sales, as well as further regulatory updates regarding insurance reimbursement for OTC monitoring devices which could further accelerate market adoption.